WHO ICTRP trial
This study is assessing the safety and tolerability of using T cell therapy…
ACTRN12613000838718 · Australian New Zealand Clinical Trials Registry (ANZCTR)
Key facts
| Trial ID | ACTRN12613000838718 |
|---|---|
| Public title | This study is assessing the safety and tolerability of using T cell therapy targeting Human Cytomegalovirus (HCMV) in treating brain cancer (glioblastoma multiforme or GBM) alongside standard treatment. |
| Scientific title | Phase I/II trial to assess safety and tolerability of autologous HCMV-specific T cell therapy as adjuvant treatment for glioblastoma multiforme. |
| Primary sponsor | QIMR Berghofer Medical Research Institute |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Study type | Interventional |
| Phase | Phase 1 / Phase 2 |
| Countries | Australia |
| Conditions | Glioblastoma multiforme (GBM); Glioblastoma multiforme (GBM);Cancer - Brain |
| Interventions | There will be a single treatment arm. Patients will be given up to six infusions every two to six weeks of 2x10e7 cells/m2 autologous HCMV-specific T cells by intravenous infusion. A minimum of 2 adoptive transfers will be given with the… |
| Registration date | Jul 30, 2013 |
| Target size | 25 |
| Secondary IDs | Nil |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: